Chris Weyrer

Chris Weyrer, M.D., Ph.D., is a Principal at Vida Ventures.
Chris holds a B.Sc. in Physics and an M.D., Ph.D. in Physiology and Neuroscience. He studied in Austria, at the University of Cambridge, and at Harvard University. During his studies, he spent time in Africa and worked at the Salk Institute on RNA biology. He won Harvard’s Healthcare Commercialization and Innovation Entrepreneurship course and collaborated with an NYC-based hedge fund on a breast cancer project.
After his studies, he secured independent research funding as a Brooks Research Fellow in Neurobiology at Harvard Medical School, where he explored potential gene therapy viruses to enhance synaptic function and plasticity.
Prior to joining Vida, Chris was a Consultant and Project Leader at Boston Consulting Group (BCG) for three years. At BCG, he worked with major clients in biopharma and private equity, focusing on strategy, R&D, clinical development, and investment decisions. His work spanned multiple fields, including neurodegenerative diseases, immuno-oncology, gene editing, and genomics.
At Vida, Chris focuses on investments and currently serves as acting Chief Business Officer at Protego Therapeutics. Other companies Chris has spent time on include LB Pharma, Kyverna, Capstan and Candid.